Saxenda vs. Ozempic (and Wegovy): Comparing Daily Liraglutide to Weekly Semaglutide

One Hormone Pathway, Two Generations of GLP-1 Therapy

When food enters your digestive tract, intestinal L-cells release glucagon-like peptide-1 (GLP-1) to stimulate glucose-dependent insulin release, slow stomach emptying, and signal fullness to appetite centers in the brain. Both liraglutide (Saxenda) and semaglutide (Ozempic / Wegovy) mimic this hormone—but structural engineering gives semaglutide a 7-day half-life compared with liraglutide’s 13-hour half-life.

Ozempic vs. Wegovy vs. Saxenda: Indications & Efficacy

In the direct head-to-head STEP 8 randomized trial, adults without diabetes who took once-weekly semaglutide 2.4 mg alongside nutrition and activity counseling lost more than twice as much body weight as those taking daily liraglutide 3.0 mg—with only 1 injection per week instead of 7.

Eligibility, Side Effects, and Safety Screening

Chronic weight-management GLP-1 prescriptions are clinically indicated for adults with a BMI of 30+, or a BMI of 27+ accompanied by a weight-related condition such as hypertension, dyslipidemia, prediabetes, or obstructive sleep apnea.

Both medications share class gastrointestinal side effects—mild nausea, early fullness, reflux, constipation, or loose stools—especially during dose escalation. Gradual 4-week titration steps, smaller low-fat meals, and steady hydration help symptoms settle. GLP-1 receptor agonists are contraindicated in pregnancy, personal or family history of medullary thyroid carcinoma (MTC), or MEN 2 syndrome, and require careful review if you have a history of pancreatitis. Explore clinician-guided weekly GLP-1 care at Amble Weight Loss.